Interestingly, targeting phosphatidylethanolamine (a phospholipid expressed on the surface of microvesicles) using duramycin selectively prevented microvesicle-associated DVT without inducing bleeding, presumably by impairing TF/FVIIa-dependent FXa generation on the microvesicle surface.5 In contrast, the direct thrombin inhibitor dabigatran was less effective in preventing tumour microvesicle-associated DVT. The gene discussed is TF; the disease is neoplasm.